How has Aurinia Pharmaceuticals's operating lease liabilities changed year-over-year?

Aurinia Pharmaceuticals's operating lease liabilities decreased by 9.7% year-over-year, from -$195K to -$214K.

What is the long-term trend for Aurinia Pharmaceuticals's operating lease liabilities?

Over 3 years (2022 to 2025), Aurinia Pharmaceuticals's operating lease liabilities has grown at a 7.1% compound annual growth rate (CAGR), from -$652K to -$802K.

Aurinia Pharmaceuticals AUPH Operating lease liabilities

Operating lease liabilities at other companies

Vera TherapeuticsVERA

——

Agios PharmaceuticalsAGIO

——

Alumis Inc.ALMS

——

Apogee Therapeutics, Inc.APGE

——

Arrowhead ResearchARWR

——

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

See full

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

See full

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

See full

Operating cash flow$32.6M+2,405%

Valuation

See full

Market cap$2.39B+78.5%

Profitability

See full

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

See full

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aurinia Pharmaceuticals's operating lease liabilities?: Aurinia Pharmaceuticals (AUPH) reported operating lease liabilities of -$214K in Q1 2026.
How has Aurinia Pharmaceuticals's operating lease liabilities changed year-over-year?: Aurinia Pharmaceuticals's operating lease liabilities decreased by 9.7% year-over-year, from -$195K to -$214K.
What is the long-term trend for Aurinia Pharmaceuticals's operating lease liabilities?: Over 3 years (2022 to 2025), Aurinia Pharmaceuticals's operating lease liabilities has grown at a 7.1% compound annual growth rate (CAGR), from -$652K to -$802K.